Status:
COMPLETED
Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This study is conducted in Africa. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 30 FlexPen® under normal clinical practice conditions.
Eligibility Criteria
Inclusion
- Type 2 diabetes having failed on basal insulin with or without OAD
- HbA1c greater than 7.0%
Exclusion
- Subjects being unlikely to comply with protocol requirements
- Subjects who previously enrolled in this study
- Subjects with hypersensitivity to biphasic insulin aspart or any of the excipients
- Women who are pregnant, breast feeding and women in child bearing capacity who are not using reliable contraceptive method
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
216 Patients enrolled
Trial Details
Trial ID
NCT00709683
Start Date
May 1 2008
End Date
May 1 2009
Last Update
March 7 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tunisia, Tunisia, 1053